CFTR and cystic fibrosis: With the advent of CFTR modulators life expectancy has been increasing, and thus, so have gastrointestinal (GI) manifestations, including gastroesophageal reflux disease, chronic abdominal pain, liver disease, exocrine pancreatic insufficiency, small intestinal bacterial overgrowth, distal intestinal obstruction syndrome (DIOS), and chronic constipation, increasingly being recognized as important complications of CF.